RecruitingPhase 2NCT07279740
Combined Brain Stimulation and Methylphenidate Treatment for Apathy in Dementia
Methylphenidate Primed iTBS for Apathy in Neurocognitive Disorders
Sponsor
Sunnybrook Health Sciences Centre
Enrollment
12 participants
Start Date
Jan 1, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
This study evaluates whether the combined treatment of methylphenidate and non-invasive brain stimulation, called intermittent theta burst stimulation, can effectively treat apathy in individuals with Alzheimer's disease or mixed AD/vascular dementia
Eligibility
Inclusion Criteria5
- Alzheimer's disease or mixed Alzheimer's disease and vascular disease
- MMSE score 10-28 inclusive
- Clinically significant apathy
- Stable dose of psychotropic medication
- Care partner must spend at least 10hrs/week with the participant
Exclusion Criteria6
- Major Depressive Episode
- Clinically significant agitation, delusions, hallucinations
- Currently talking a dopaminergic agent other than methylphenidate
- Failure to clear the TMS adult safety scale (e.g. unapproved pacemakers, metallic implants, history of epilepsy)
- Central nervous system abnormalities (other than Alzheimer's disease) deemed clinically significant by study physician or seizures
- Any condition that in the opinion of the study physician, makes it medically unsafe for the patient to enroll in the trial
Interventions
DEVICEintermittent theta burst stimulation (iTBS)
iTBS is a form of repetitive transcranial magnetic simulation (rTMS), a non-invasive form of brain stimulation.
DRUGMethylphenidate (MPH)
Participants will be on methylphenidate clinically prior to the trial
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07279740
Related Trials
PET Imaging of Phosphodiesterase-4 (PDE4) in Volunteers With Alzheimer Disease (AD) or Mild Cognitive Impairment (MCI)
NCT071696301 location
Novel Augmentation of DAOIB and Antioxidant for Early Dementia
NCT064675391 location
A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
NCT06937229241 locations
Brain Blood Flow and Sugar Transport in Alzheimer's Disease With and Without Diabetes - A Pilot Imaging Study
NCT074820721 location
Lombard Cohort of Brain Health Services
NCT074571385 locations